company background image
GTBP

GT BiopharmaNasdaqCM:GTBP Stock Report

Last Price

US$2.62

Market Cap

US$79.9m

7D

-14.9%

1Y

-65.0%

Updated

19 Jan, 2022

Data

Company Financials +
GTBP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GTBP Stock Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

Price History & Performance

Summary of all time highs, changes and price drops for GT Biopharma
Historical stock prices
Current Share PriceUS$2.62
52 Week HighUS$19.73
52 Week LowUS$2.55
Beta1.53
1 Month Change-27.22%
3 Month Change-60.48%
1 Year Change-64.96%
3 Year Change-77.00%
5 Year Change-99.39%
Change since IPO-100.00%

Recent News & Updates

Nov 24
Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

GTBPUS BiotechsUS Market
7D-14.9%-6.2%-4.6%
1Y-65.0%-19.8%7.7%

Return vs Industry: GTBP underperformed the US Biotechs industry which returned -18.4% over the past year.

Return vs Market: GTBP underperformed the US Market which returned 10.2% over the past year.

Price Volatility

Is GTBP's price volatile compared to industry and market?
GTBP volatility
GTBP Average Weekly Movement11.4%
Biotechs Industry Average Movement10.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.4%

Stable Share Price: GTBP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: GTBP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19653Greg Berkhttps://www.gtbiopharma.com

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection.

GT Biopharma Fundamentals Summary

How do GT Biopharma's earnings and revenue compare to its market cap?
GTBP fundamental statistics
Market CapUS$79.93m
Earnings (TTM)-US$46.28m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GTBP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$46.28m
Earnings-US$46.28m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.52
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.1%

How did GTBP perform over the long term?

See historical performance and comparison

Valuation

Is GT Biopharma undervalued compared to its fair value and its price relative to the market?

2.49x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GTBP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GTBP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GTBP is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GTBP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GTBP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GTBP is overvalued based on its PB Ratio (2.5x) compared to the US Biotechs industry average (2.1x).


Future Growth

How is GT Biopharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-9.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GTBP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GTBP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GTBP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GTBP is forecast to have no revenue next year.

High Growth Revenue: GTBP is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GTBP's Return on Equity is forecast to be high in 3 years time


Past Performance

How has GT Biopharma performed over the past 5 years?

6.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GTBP is currently unprofitable.

Growing Profit Margin: GTBP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GTBP is unprofitable, but has reduced losses over the past 5 years at a rate of 6.2% per year.

Accelerating Growth: Unable to compare GTBP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: GTBP has a negative Return on Equity (-145.19%), as it is currently unprofitable.


Financial Health

How is GT Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: GTBP's short term assets ($35.8M) exceed its short term liabilities ($3.9M).

Long Term Liabilities: GTBP has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: GTBP has more cash than its total debt.

Reducing Debt: GTBP had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GTBP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GTBP has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 18.3% each year.


Dividend

What is GT Biopharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GTBP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GTBP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GTBP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GTBP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GTBP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Greg Berk (63 yo)

1

Tenure

US$2,500

Compensation

Dr. Gregory I. Berk, also known as Greg, M.D., serves as Member of Scientific Advisor Board at GT Biopharma, Inc. Dr. Berk serves as Director at Inflection Biosciences Ltd since October 2020. He serves as...


Leadership Team

Experienced Management: GTBP's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: GTBP's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 503.3%.


Top Shareholders

Company Information

GT Biopharma, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: GT Biopharma, Inc.
  • Ticker: GTBP
  • Exchange: NasdaqCM
  • Founded: 1965
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$79.932m
  • Shares outstanding: 30.51m
  • Website: https://www.gtbiopharma.com

Number of Employees


Location

  • GT Biopharma, Inc.
  • 9350 Wilshire Boulevard
  • Suite 203
  • Beverly Hills
  • California
  • 90212
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:33
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.